Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A comparative review of the adverse effect profiles of heparins and heparinoids.

Literature DB >> 7537967

A comparative review of the adverse effect profiles of heparins and heparinoids.

Abstract

On the basis of the results of the 11 studies reviewed, thromboprophylaxis with unfractionated heparin, low molecular weight (LMW) heparin or a heparinoid (danaparoid sodium; Org 10172) in patients undergoing total hip replacement did not show any important clinical differences with respect to the tolerability profiles of the different compounds. However, as a result of the great variability in the presentation and evaluation of blood losses and bleeding complications in these studies, it is mandatory to perform a direct comparison of the different compounds in question in a double-blind, prospective clinical study.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1995 PMID： 7537967 DOI： 10.2165/00002018-199512010-00002

Source DB: PubMed Journal: Drug Saf ISSN： 0114-5916 Impact factor: 5.606

25 in total

1. Hyper-transaminasemia with heparin therapy.

Authors: M Sonnenblick; A Oren; W Jacobsonn
Journal: Br Med J Date: 1975-07-12

2. Clinical trials with low molecular weight heparins in the prevention of postoperative thromboembolic complications: a meta-analysis.

Authors: M R Lassen; L C Borris; H M Christiansen; P Schøtt; A D Olsen; J V Sørensen; H Rahr; H P Jensen
Journal: Semin Thromb Hemost Date: 1991 Impact factor: 4.180

3. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin.

Authors: B I Eriksson; P Kälebo; B A Anthymyr; H Wadenvik; L Tengborn; B Risberg
Journal: J Bone Joint Surg Am Date: 1991-04 Impact factor: 5.284

4. The effect of intravenous fixed-dose heparin during total hip arthroplasty on the incidence of deep-vein thrombosis. A randomized, double-blind trial in patients operated on with epidural anesthesia and controlled hypotension.

Authors: N E Sharrock; W W Brien; E A Salvati; R Mineo; K Garvin; T P Sculco
Journal: J Bone Joint Surg Am Date: 1990-12 Impact factor: 5.284

5. Low-molecular-weight heparin (enoxaparin) vs dextran 70. The prevention of postoperative deep vein thrombosis after total hip replacement. The Danish Enoxaparin Study Group.

Authors:
Journal: Arch Intern Med Date: 1991-08

6. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery.

Authors: M Dechavanne; D Ville; M Berruyer; F Trepo; F Dalery; N Clermont; J L Lerat; B Moyen; L P Fischer; A Kher
Journal: Haemostasis Date: 1989

10. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group.

Authors:
Journal: Arch Orthop Trauma Surg Date: 1992 Impact factor: 3.067

2 in total

Review 1. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors: R Davis; D Faulds
Journal: Drugs Aging Date: 1997-04 Impact factor: 3.923

Review 2. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.

Authors: M I Wilde; A Markham
Journal: Drugs Date: 1997-12 Impact factor: 9.546